Teva asks FTC to reopen Actavis and Watson merger decision

24-10-2018

Teva asks FTC to reopen Actavis and Watson merger decision

parbradyphoto / iStockphoto.com

The US Federal Trade Commission (FTC) yesterday said that Teva Pharmaceuticals has asked the commission to reopen and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.


supply agreement, generic, generic drugs, big pharma, US Federal Trade Commission, FTC, Teva Pharmaceuticals, Pfizer, Allergan, Actavis

LSIPR